Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey.
Fiche publication
Date publication
janvier 2021
Journal
Therapeutic advances in musculoskeletal disease
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MARTIN Thierry
Tous les auteurs :
Petitdemange A, Felten R, Sibilia J, Martin T, Arnaud L
Lien Pubmed
Résumé
Antimalarial agents (AMs), mainly hydroxychloroquine (HCQ) and chloroquine, are the cornerstone of treatment of cutaneous and systemic lupus erythematosus. However, many aspects of AM prescription remain empirical. The aim of this study was to assess the modalities of AM prescription among physicians treating patients with lupus and to verify the assumption that AM use is heterogeneous and frequently at variance with international guidelines.
Mots clés
antimalarial agents, care survey, cutaneous lupus erythematosus, health, systemic lupus erythematosus
Référence
Ther Adv Musculoskelet Dis. 2021 ;13:1759720X211002595